Contribute Try STAT+ Today

Top of the morning to you and a fine one it is. Despite gloomy skies hovering over the Pharmalot campus, we are maintaining a sunny outlook today. And why not? Our short person is sleeping in and our official mascot is almost always sleeping. This leaves us to our own devices, such as they are. First on the list:  firing up the coffee kettle to brew a cup of stimulation; coconut is the choice today, by the way. From there, we will dive into the to-do list. Meanwhile, here are some tidbits for you. Have a lovely day and do keep in touch.

The federal government filed a lawsuit accusing Gilead Sciences (GILD) of infringing patents on a pair of HIV prevention pills and unfairly reaping hundreds of millions of dollars from research funded by taxpayers, STAT reports. The patents are held by the Centers for Disease Control and Prevention, which helped fund academic research into HIV prevention that later formed the basis for two pills sold by the drug maker. The Department of Health and Human Services contended that Gilead refused to reach a licensing agreement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.